HAEMONETICS CORP
No enriched coverage for $HAE in the last 7 days.
No SEC Form 4 filings for $HAE in the last 30 days.
See all $HAE insider activity →Mizuho maintained an Outperform rating for Haemonetics (HAE) and raised its price target to $140 from $95, a 47.37% increase. The stock is currently priced at $116.90, which is 35.3% over its GF Value™ of $86.42, according to GuruFocus. HAE has a GF Score™ of 76/100, with strengths in profitability and growth but concerns about valuation. Seven gurus hold positions in HAE, with five increasing their stakes recently.
CSL Plasma will expand its supply agreement with Haemonetics (HAE) to all 300+ U.S. plasma donation centers, transitioning to the NexSys PCS platform by 2027. The deal ends CSL's partnership with Terumo BCT, which estimates a $610M impact. Haemonetics stock rose 17% to $119 per share.
Pacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
Recent HAE coverage spans market movers, financial news and earnings.
Target raise suggests potential upside for the stock.
The new contract expands Haemonetics' market share in US plasma collection, driving strong buying pressure.
Positive reaction to revenue growth and EPS beat.
Shares jumped 17.46% to $119.47.
Haemonetics Corporation's average stock price target increased from $113.5 to $115.5, with a range of $86 to $140, according to 10 analysts. This implies a 14% upside from the Oct. 7 closing price. The consensus rating remains 'Buy' among 12 analysts, with 9 Buys and 3 Holds.
AlphAI scores every news story that mentions HAE with an AI model for sentiment and relevance, and aggregates insider trades from HAEMONETICS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Mizuho maintained an Outperform rating for Haemonetics (HAE) and raised its price target to $140 from $95, a 47.37% increase. The stock is currently priced at $116.90, which is 35.3% over its GF Value™ of $86.42, according to GuruFocus. HAE has a GF Score™ of 76/100, with strengths in profitability and growth but concerns about valuation. Seven gurus hold positions in HAE, with five increasing their stakes recently.
1 min readCSL Plasma will expand its supply agreement with Haemonetics (HAE) to all 300+ U.S. plasma donation centers, transitioning to the NexSys PCS platform by 2027. The deal ends CSL's partnership with Terumo BCT, which estimates a $610M impact. Haemonetics stock rose 17% to $119 per share.
1 min readPacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
2 min readOn 8 October 2026, Haemonetics (HAE) rose 17.46% to $119.47, while Applied Optoelectronics (AAOI) fell 13.58% to $105.90. Other notable movers included Veradermics (MANE), Securitize (SECZ), The Vita Coco Company (COCO), Erasca (ERAS), MaxLinear (MXL), argenx (ARGX), EquipmentShare.com (EQPT), and Hut 8 (HUT).
2 min readHaemonetics Corporation's average stock price target increased from $113.5 to $115.5, with a range of $86 to $140, according to 10 analysts. This implies a 14% upside from the Oct. 7 closing price. The consensus rating remains 'Buy' among 12 analysts, with 9 Buys and 3 Holds.
1 min readBTIG kept a Buy rating on Haemonetics with a $130 price target, implying 27.8% upside. The firm cited a new CSL Plasma agreement and raised the valuation multiple to 21x, citing growth prospects and strong margins.
1 min readSTAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.
4 min readMidday trading saw Marathon Petroleum (MPC) and APA up over 4% on rising oil prices. Chipotle (CMG) rose 6% on Starbucks (SBUX) acquisition rumors, while Starbucks fell 5%. Skydance (SKD) gained 4% on CEO comments. Levi Strauss (LEVI) dropped 3% after lowering revenue forecasts. GlobalFoundries (GFS) rose 5% on a $2B manufacturing deal. Haemonetics (HAE) surged 16% on CSL's platform rollout plans. Broadcom (AVGO) fell 1% amid AI chip financing reports.
7 min readLevi's (LEVI) shares fell 3.7% after softer DTC sales growth, though earnings beat estimates. Starbucks (SBUX) dropped 3% amid takeover speculation. Argenx (ARGX) fell 15% after discontinuing a drug trial. Haemonetics (HAE) rose 13% on CSL's device rollout plan. Tilray (TLRY) reported record revenue. Wolfspeed (WOLF) gained 11% on a $1.5B US DoD loan. Palantir (PLTR) rose 3% after a Goldman upgrade. Globalfoundries (GFS) rose 3% on a $2B TSMC deal. Helen of Troy (HELE) raised its profit outlook.
3 min readUS equity futures decline as oil prices surge due to reports of potential US strikes on Iran and a tanker attack in the Persian Gulf. The S&P 500 is down 0.4%, Nasdaq futures fall 0.5%, and the Russell 2000 hits a 4-month low. Tesla (TSLA) and Nvidia (NVDA) underperform, while Microsoft (MSFT) and Apple (AAPL) edge higher. Bond yields rise, with the 10-year yield near 5.35%. Energy stocks gain as Hurricane Isaias forces Gulf producers to shut wells.
7 min read
